ÐÇ¿ÕÓéÀÖ¹ÙÍø- BRFSS – ACBS 2023 Adult Prevalence Table 7

Table 7: Estimated percent using an inhaled corticosteroid in the past 3 months among adults1 with current2 asthma status by state/territory – BRFSS Asthma Call-back Survey, United States, 2023.
State/Territory Current
Sample
size±
% SE§ 95% CI
Arizona 394 27.9 3.6 (20.8 – 35.0)
California 296 28.7 4.0 (20.9 – 36.5)
Connecticut 463 28.1 3.0 (22.2 – 34.0)
Florida 385 24.8 4.2 (16.6 – 33.0)
Georgia 284 29.6 4.3 (21.2 – 38.0)
Hawaii 200 31.7 4.9 (22.1 – 41.3)
Indiana 540 26.8 2.3 (22.3 – 31.3)
Iowa 296 36.2 3.9 (28.6 – 43.8)
Kansas 255 33.1 3.9 (25.5 – 40.7)
Kentucky 225 21.1 4.4 (12.5 – 29.7)
Maine 399 32.6 3.6 (25.5 – 39.7)
Massachusetts 252 34.7 4.1 (26.7 – 42.7)
Michigan 518 29.5 2.6 (24.4 – 34.6)
Minnesota 463 30.3 3.0 (24.4 – 36.2)
Missouri 208 25.9 4.1 (17.9 – 33.9)
Montana 176 41.3 5.9 (29.7 – 52.9)
Nebraska 365 31.2 3.4 (24.5 – 37.9)
New Hampshire 386 30.3 3.5 (23.4 – 37.2)
New Jersey 302 23.4 3.1 (17.3 – 29.5)
New York 277 30.7 4.0 (22.9 – 38.5)
Ohio 381 26.6 3.2 (20.3 – 32.9)
Rhode Island 243 28.7 4.0 (20.9 – 36.5)
Texas 205 31.8 5.7 (20.6 – 43.0)
Utah 434 27.7 3.0 (21.8 – 33.6)
Vermont 466 40.0 3.0 (34.1 – 45.9)
Wisconsin 412 24.2 2.8 (18.7 – 29.7)
Puerto Rico 287 19.4 3.0 (13.5 – 25.3)
27 States / Area 9,112 28.6 1.1 (26.4 – 30.8)
Median 29.5
Range 19.4-41.3

 

1 Aged ≥ 18 years

2 “Yes” response to “Do you still have asthma?”

± Sample size for adults with current asthma, excludes “DK/Refused”

§ Standard error

Confidence interval

Link for Summary Data Quality Report: /brfss/acbs/2023/pdf/sdq_report_acbs_23-508.pdf